MARC details
000 -LEADER |
fixed length control field |
03773nam a22004935i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-030-87849-8 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729134618.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
211219s2022 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9783030878498 |
-- |
978-3-030-87849-8 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MBGR |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED106000 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MBGR |
Source |
thema |
245 10 - TITLE STATEMENT |
Title |
Gene and Cellular Immunotherapy for Cancer |
250 ## - EDITION |
Edition statement |
1st ed. 2022. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Cham : |
Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
-- |
Imprint: Humana, |
Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
X, 378 p. 29 illus., 28 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Cancer Drug Discovery and Development, |
International Standard Serial Number |
2196-9914 |
505 0# - CONTENTS |
Contents |
The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index. |
520 ## - ABSTRACT |
Abstract |
Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by adiverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Medicine |
General subdivision |
Research. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Biology |
General subdivision |
Research. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Medical microbiology. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Pharmacology. |
9 (RLIN) |
7400 |
650 14 - SUBJECT HEADINGS |
Subject term |
Biomedical Research. |
650 24 - SUBJECT HEADINGS |
Subject term |
Medical Microbiology. |
650 24 - SUBJECT HEADINGS |
Subject term |
Pharmacology. |
9 (RLIN) |
7400 |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Ghobadi, Armin. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
DiPersio, John F. |
Relator term |
editor. |
710 2# - ADDED CORPORATE NAME |
Added corporate author |
SpringerLink (Online service) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Cancer Drug Discovery and Development, |
International Standard Serial Number |
2196-9914 |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
245 ## - TITLE STATEMENT |
Medium |
[E-Book] |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
912 ## - |
-- |
ZDB-2-SME |
912 ## - |
-- |
ZDB-2-SXM |